Taiwan Liposome Company is a specialty pharmaceutical company with a proprietary drug delivery technologies based on a lipid formulation platform. The company, founded in 1997, has its eyes set on both the western markets and the Asia Pacific markets. It has a range of products that suit the needs of the different markets.

TLC has won a number of awards for its R&D and innovation. In an interview with BioSpectrum Asia, Mr George Yeh, president, TLC, talks about the plans to take the company forward and spread wings abroad. Mr Yeh earned his BA from the University of California at Berkeley and his MA and MBA from the University of Michigan at Ann Arbor. He has been hailed as an outstanding young innovator by the Ministry of Economic Affairs, Taiwan.

TLC signed a collaboration agreement with Teva in March 2012? Are there other such collaborations in the offing?

We've out-licensed the distribution right of our generic cancer products for the US territory to Teva, with other territories currently under negotiation. Several multinational pharmas are also approaching TLC for collaboration opportunities of our other products. Details will be announced shortly once deals are confirmed.

Brief us about the latest R&D work happening in TLC?

TLC has always been a very focused company, specializing in the development of products and platforms along the line of "Lipid-based Drug Delivery Systems". We have developed five technology platforms that can encapsulate different sized molecules for different release profiles ranging from minutes to months, and we have applied the technology platforms in developing six products along the "super generic", "new formulation" and "NCE" categories.